Provided by Tiger Trade Technology Pte. Ltd.

eXoZymes Inc

5.83
-0.2700-4.43%
Volume:2K
Turnover:11.97K
Market Cap:54.11M
PE:-4.85
High:6.20
Open:5.77
Low:5.77
Close:6.10
52wk High:18.40
52wk Low:4.35
Shares:9.28M
Float Shares:7.19M
Volume Ratio:0.27
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2028
EPS(LYR):-1.0927
ROE:-187.16%
ROA:-74.74%
PB:14.81
PE(LYR):-5.34

Loading ...

Exozymes Schedules Annual Shareholder Meeting

Reuters
·
Sep 19

eXoZymes Selects Curia to Scale up NCT Manufacturing Process for Commercial Production

Reuters
·
Sep 08

Exozymes CEO Michael Heltzen Reports $59,978 Common Share Purchase

Reuters
·
Sep 03

eXoZymes Inc trading resumes

TIPRANKS
·
Aug 26

NASDAQ Trade Halt Volatility Trading Pause at 03:52 Pm

Reuters
·
Aug 26

Exozymes Says Optimized NCT Process Lifts Manufacturing Productivity 10-Fold

Reuters
·
Aug 19

Exozymes FY26 Q2 Net Loss Widens 22% to $2.88 Million; Revenue Remains no Revenue

Reuters
·
Aug 14

eXoZymes Menjadwalkan Konferensi Pers Kuartal II 2026 Lewat Webinar

Reuters
·
Aug 12

NASDAQ Trade Halt Volatility Trading Pause at 09:35 Am

Reuters
·
Jul 15

Exozymes Prices Registered Direct Offering at USD 18 Per Unit, Raising USD 639,990 Gross

Reuters
·
Jul 02

Exozymes Wins USD 2.03 Million NIH Grant for Cannabinoid Analog Development

Reuters
·
Jun 26

Exozymes Wins NIH Grant Worth $2.03 Million for Cannabinoid Analog Development

Reuters
·
Jun 25

eXoZymes closes USD 5.95 million follow-on offering of stock and warrants

Reuters
·
Jun 18

EXoZymes Prices $5.3 Million Offering

MT Newswires Live
·
Jun 08

eXoZymes prices 592,270 shares at $18.00 in public offering

TIPRANKS
·
Jun 08

eXoZymes prices public offering of stock-warrant units at $18, raising $5.33 million gross

Reuters
·
Jun 08

Exozymes Q1 FY26 net loss widens 27.7% to $2.37 million

Reuters
·
May 15

eXoZymes announces graduation from Shell GameChanger Accelerator

TIPRANKS
·
May 08

Exozymes CSO Tyler Korman disposes of USD 15,424 common shares

Reuters
·
Apr 11

eXoZymes CCO says NCTx targets supplement launch for NCT, eyes pharma options

Reuters
·
Apr 10